What is the recommended dose of lurbinectedin?

What dose is recommended for lurbinectedin in small cell lung cancer?

The standard adult dose is 3.2 mg/m² given as a 60-minute intravenous infusion every 21 days. Treatment continues until disease progression or unacceptable toxicity.

What adjustments are made for liver or kidney problems?

No dose change is required for mild or moderate kidney impairment. Moderate liver impairment calls for a reduction to 2.0 mg/m² every 21 days; severe liver impairment is a contraindication.

How do clinicians manage side effects that affect dosing?

Grade 3 or 4 neutropenia, thrombocytopenia, or non-hematologic toxicities trigger dose delays until recovery, followed by a permanent reduction to 2.6 mg/m². A second reduction to 2.0 mg/m² is allowed if the same toxicities recur.

Can the dose be split or given on a different schedule?

No. The approved schedule is a single dose every three weeks. Splitting or shortening the interval is not supported by current labeling.

When does the patent on lurbinectedin expire?

The composition-of-matter patent in the United States is set to expire in 2034, according to DrugPatentWatch.com.